Perfint has already started to sell the product in India, China and eastern Europe and the company now expects its revenues to double to Rs 100 crore after receiving approval from the FDA to expand its reach in the US market as well.
"This is a Holy Grail from regulatory perspective. This gives us a leverage not only to access the US market, but other global markets as well. The American market is tightly contested, but our product is among a few devices that offer integrated assistance, from spotting the cancer to planning the placement of needles to removing it", Perfint co-founder and CEO, S Nandakumar said.
Source: Medindia
